ROX INDEX IN PATIENTS WITH COVID-19 WHO USED HIGH FLOW THERAPY AND ELMO
DOI:
https://doi.org/10.54620/cadesp.v15i2.671Keywords:
COVID-19, noninvasive ventilation, Respiratory Insufficiency.Abstract
To evaluate the ROX index in monitoring patients with respiratory failure by COVID-19. Cross-sectional study carried out at the Hospital São José, in Ceará. Patients with COVID-19, hospitalized from January to July, who used high flow oxygen therapy (HFT) combined with ELMO were included. Data were collected by review of medical records. Statistical analyses were performed with Excel Microsoft 365 software. Forty patients were included in this research. Most were male (67.5%). The mean of age was 51.9 years; 65% of patients were successful with TAF/ELMO therapy. ROX index was a predictor of success or failure at the 24th and 48th hours. There was a strong correlation between the ROX index and the final PaO2/FiO2. Low ROX index values were associated with a higher risk of intubation.
Downloads
References
Ranzani OT, Bastos LSL, Gelli JGM, et al. Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407-418. doi:10.1016/S2213-2600(20)30560-9
Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020;323(16):1545-1546. doi:10.1001/jama.2020.4031
Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020 Nov;28:100570. doi: 10.1016/j.eclinm.2020.100570.
Vianello A, Arcaro G, Molena B, Turato C, Sukthi A, Guarnieri G. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax. 2020 Nov;75(11):998–1000. doi: 10.1136/thoraxjnl-2020-214993.
Franco C, Facciolongo N, Tonelli R, Dongilli R, Vianello A, Pisani L. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J. 2020 Nov 5;56(5) doi: 10.1183/13993003.02130-2020.
Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respir Res. 2020 Aug;7(1) doi: 10.1136/bmjresp-2020-000650.
Vega ML, Pisani L. Nasal high flow oxygen in acute respiratory failure. Pulmonology. 2021 Feb 13 doi: 10.1016/j.pulmoe.2021.01.005. S2531-0437(21)00038-6https://doi.org/Epubahead of print.
Tonetti T, Grasselli G, Zanella A, Pizzilli G, Fumagalli R, Piva S. COVID-19 Northern Italian ICU Network. Use of critical care resources during the first 2 weeks (February 24-March 8, 2020) of the Covid-19 outbreak in Italy. Ann Intens Care. 2020 Oct 12;10(1):133. doi: 10.1186/s13613-020-00750-z.
Coppadoro, A., Benini, A., Fruscio, R. et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Crit Care. 2021; 25:80.
Holanda MA, Tomaza BS, Menezesa DGA, Linoa JA, Gomesa GC. ELMO 1.0: a helmet interface for CPAP and high-flow oxygen delivery. J Bras Pneumol. 2021;47(3):e20200590.
Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respiratory Care. 2016; 61(4): 529-54.
Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intens Care Med. 2015 Apr;41(4):623–632. doi: 10.1007/s00134-015-3693-5.
Suliman LA, Abdelgawad TT, Farrag NS, Abdelwahab HW. Validity of ROX index in prediction of risk of intubation in patients with COVID-19 pneumonia. Adv Respir Med. 2021;89(1):1-7. doi: 10.5603/ARM.a2020.0176.
Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. J Crit Care. 2016 Oct;35:200–205. doi: 10.1016/j.jcrc.2016.05.022.
Blez D, Soulier A, Bonnet F, et al. Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate. Intensive Care Med. 2020; 46(11): 2094–2095.
Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016; 35: 200–205.
Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019; 199(11): 1368–1376.
Hill NS, Ruthazer R. Predicting outcomes of high-flow nasal cannula for acute respiratory distress syndrome. An index that ROX. Am J Respir Crit Care Med. 2019; 199(11): 1300–1302.
Rodriguez M, Thille AW, Boissier F, et al. Predictors of successful separation from high-flow nasal oxygen therapy in patients with acute respiratory failure: a retrospective monocenter study. Ann Intensive Care. 2019; 9(1): 101.
Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, Jia J, Xie C. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med. 2020 Dec 24;20(1):324. doi: 10.1186/s12890-020-01354-w
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
Categories
License
Copyright (c) 2021 Cadernos ESP
This work is licensed under a Creative Commons Attribution 4.0 International License.
Accepted 2021-09-29
Published 2021-12-07
